NO872659L - Farmastiske preparater med galaktitol som bŸrer. - Google Patents

Farmastiske preparater med galaktitol som bŸrer.

Info

Publication number
NO872659L
NO872659L NO872659A NO872659A NO872659L NO 872659 L NO872659 L NO 872659L NO 872659 A NO872659 A NO 872659A NO 872659 A NO872659 A NO 872659A NO 872659 L NO872659 L NO 872659L
Authority
NO
Norway
Prior art keywords
galactitol
weight
parts
water
pharmaceuticals
Prior art date
Application number
NO872659A
Other languages
English (en)
Other versions
NO872659D0 (no
Inventor
Daniel Lee Francis
Original Assignee
Cetus Ben Venue Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Ben Venue Therapeutics filed Critical Cetus Ben Venue Therapeutics
Publication of NO872659D0 publication Critical patent/NO872659D0/no
Publication of NO872659L publication Critical patent/NO872659L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO872659A 1986-06-26 1987-06-25 Farmastiske preparater med galaktitol som bŸrer. NO872659L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/879,143 US4797388A (en) 1984-05-21 1986-06-26 Pharmaceutical compositions with galactitol as carrier

Publications (2)

Publication Number Publication Date
NO872659D0 NO872659D0 (no) 1987-06-25
NO872659L true NO872659L (no) 1987-12-28

Family

ID=25373508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO872659A NO872659L (no) 1986-06-26 1987-06-25 Farmastiske preparater med galaktitol som bŸrer.

Country Status (9)

Country Link
US (1) US4797388A (no)
EP (1) EP0251657B1 (no)
JP (1) JPS6322527A (no)
AT (1) ATE68978T1 (no)
AU (1) AU599111B2 (no)
DE (1) DE3774192D1 (no)
DK (1) DK330787A (no)
FI (1) FI872831A (no)
NO (1) NO872659L (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2040394T3 (es) * 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5141925A (en) * 1990-04-23 1992-08-25 Trustees Of Tufts College Vivo methods for treating coccidiosis
GB2271281A (en) * 1992-10-09 1994-04-13 Orion Yhtymae Oy Stabilised cyclophosphamide compositions
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US7695736B2 (en) * 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
CN100375622C (zh) * 2003-11-25 2008-03-19 范敏华 一种氟尿嘧啶冻干粉针剂及其制备方法
WO2006089002A2 (en) * 2005-02-15 2006-08-24 Yale University Method for high throughput screening for antibodies and proteins inducing apoptosis
US7989631B2 (en) * 2006-02-10 2011-08-02 Amgen Inc. Hydrate forms of AMG706
US10149857B2 (en) 2017-03-09 2018-12-11 Ampac Fine Chemicals Llc Lyophilized cyclophosphamide composition and methods of preparation thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1079397A (en) * 1965-01-13 1967-08-16 Chinoin Gyogyszer Es Vegyeszet 1,6-dibromo-1,6-dideoxy dulcitol and pharmaceutical compositions containing it
US3384546A (en) * 1965-05-28 1968-05-21 Miles Lab Directly compressed low-density crystalline sorbitol pharmaceutical tablets
US3944625A (en) * 1973-02-02 1976-03-16 Georgia-Pacific Corporation Separation of mannitol from galactitol
FI53651C (fi) * 1976-06-24 1979-05-15 Farmos Oy Fodervitaminloesning eller -emulsion
JPS5920647B2 (ja) * 1976-10-01 1984-05-15 武田薬品工業株式会社 注射剤
JPS56127321A (en) * 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Preparation of gamma-globulin pharmaceutical
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第7因子含有水溶液の加熱処理方法
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
IT1151126B (it) * 1982-03-30 1986-12-17 Pirelli Procedimento e apparecchiatura per la fabbricazione di pneumatici
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPH0651641B2 (ja) * 1983-08-29 1994-07-06 株式会社ミドリ十字 ガンマ・インターフェロン組成物
EP0133767B1 (en) * 1983-08-04 1991-04-03 The Green Cross Corporation Gamma interferon composition
US4659699A (en) * 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
JPS60190711A (ja) * 1984-03-09 1985-09-28 Tokyo Tanabe Co Ltd プロトポルフイリン類注射用製剤
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
EP0225581A3 (en) * 1985-11-30 1989-05-24 Green Cross Corporation Method for the heat-treatment of immunoglobulins and immunoglobulin product

Also Published As

Publication number Publication date
AU7470287A (en) 1988-01-07
EP0251657A2 (en) 1988-01-07
NO872659D0 (no) 1987-06-25
FI872831A0 (fi) 1987-06-26
AU599111B2 (en) 1990-07-12
DK330787D0 (da) 1987-06-26
EP0251657A3 (en) 1988-06-22
JPS6322527A (ja) 1988-01-30
US4797388A (en) 1989-01-10
EP0251657B1 (en) 1991-10-30
ATE68978T1 (de) 1991-11-15
DK330787A (da) 1987-12-27
FI872831A (fi) 1987-12-27
DE3774192D1 (de) 1991-12-05

Similar Documents

Publication Publication Date Title
DK0395329T4 (da) Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
NO872659L (no) Farmastiske preparater med galaktitol som bŸrer.
DE3688114D1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
ATE76747T1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DE69223914D1 (de) 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
ATE84032T1 (de) Benzimidazolderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
FR2679906B1 (fr) Nouvelles (isoquinolein-5 yl) sulfonamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
MC2025A1 (fr) Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
PT89802A (pt) Processo para a preparacao de uma composicao farmaceutica, contendo o factor xiii de coagulacao do sangue humano, para a prevencao da hemorragia intraventricular em criancas permaturas
ES2198424T3 (es) Soluciones inyectables listas para el empleo que contienen doxorrubicina.
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
DE3866198D1 (de) Pharmazeutische zubereitung fuer die intrarektale verabreichung von calcitonin und daraus hergestellte einzeldosisformen.
ES2036539T3 (es) Un procedimiento para preparar derivados de ergolina.
ATE118033T1 (de) Prourokinasederivate mit niedrigem molekulargewicht und sie enthaltende pharmazeutische zusammensetzungen.
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
ES2016052A6 (es) Procedimiento para preparar derivados de adenosinmonofosfonato (amp) ciclico y de guanosinmonofosfonato (gmp) ciclico.
FI810643L (fi) I 10-staellning substituerade 5-cyanmetylendibenzo /a d/ cyklohepten foerfarande foer deras framstaellning och terapeutiska medel innehaollande dem